Paneez E. Khoury

Internal Medicine

50 Rockville Pike
Bethesda, MD 20892

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Journal: Nature medicine

Published: May 05, 2026

Reply to "Touchstones of compassionate care in allergy-immunology beyond artificial intelligence: connection and generational legacy".

Reply to "Touchstones of compassionate care in allergy-immunology beyond artificial intelligence: connection and generational legacy".

Journal: The journal of allergy and clinical immunology. In practice

Published: January 17, 2026

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: January 09, 2026

Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.

Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.

Journal: Journal of leukocyte biology

Published: January 02, 2026

Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.

Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.

Journal: Journal of leukocyte biology

Published: January 02, 2026

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Journal: Nature medicine

Published: October 24, 2025

Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.

Circulating eosinophils in patients with hypereosinophilic syndrome have heterogeneous immunophenotypes.

Journal: The journal of allergy and clinical immunology. Global

Published: September 05, 2025

Clinical relevance of mosaic variants detected by exome sequencing.

Clinical relevance of mosaic variants detected by exome sequencing.

Journal: The Journal of allergy and clinical immunology

Published: September 03, 2025

Prediction model to identify patients with hypereosinophilic syndrome using real-world data.

Prediction model to identify patients with hypereosinophilic syndrome using real-world data.

Journal: The journal of allergy and clinical immunology. Global

Published: June 09, 2025

The Clinical Burden of Hypereosinophilic Syndrome in a Large United States Cohort.

The Clinical Burden of Hypereosinophilic Syndrome in a Large United States Cohort.

Journal: The journal of allergy and clinical immunology. In practice

Published: June 05, 2025

Preparing Allergists to Practice in 2050 Using Artificial Intelligence.

Preparing Allergists to Practice in 2050 Using Artificial Intelligence.

Journal: The journal of allergy and clinical immunology. In practice

Published: May 09, 2025

Leveraging artificial intelligence for medical education in allergy and immunology.

Leveraging artificial intelligence for medical education in allergy and immunology.

Journal: The Journal of allergy and clinical immunology

Published: April 07, 2025

Showing 1-12 of 96

Last Updated: 09/26/2026